Abstract:Background: Cutaneous melanoma is rare in children with a global incidence of two to five cases per million people per year, accounting for roughly 1% of all pediatric malignancies.5 However, the incidence of pediatric melanoma in the United States is increasing.1 Mohs Micrographic Surgery (MMS) is a standard treatment for adult skin cancer due to its low recurrence rates and tissue preservation. However, it is less commonly used to treat melanoma in children because the required infrastructure is not widely accessible and many pediatric surgeons are not familiar with MMS.4 With more limited treatment options for pediatric melanoma, it is important to question the role of socioeconomic factors that may contribute to MMS treatment of pediatric patients with melanoma.2 Purpose: The purpose of the study is to investigate pediatric patients with melanoma and assess their tumor characteristics by comparing various skin cancer treatments (Mohs, other treatments [local excision], or no treatment).Methods: This is a retrospective cohort study of pediatric patients (age < 21 years) diagnosed with cutaneous Melanoma who received MMS between 2004 and 2020 in the National Cancer Database (NCDB). Descriptive statistics were collected on the following variables: the year of diagnosis, sex, race, tumor stage, tumor behavior, primary site, and surgical procedure. Overall survival was determined via the Kaplan-Meier test. Results: 104 cases of pediatric melanoma treated with MMS were identified. Per statistical analysis, it does not appear that surgical frequency has varied yearly from 2004 to 2020 (r2 = 0). The median age of patients analyzed was 18 years old. Most patients were female (64.4%, N = 67), White (100%, N=104), non-Hispanic (100%, N=104), and had private insurance (87.3%, N = 90). 70.2% (N=73) of cases were defined as early-stage (stage 0 or I). 72.1% (N=75) of cases were identified as invasive. 45.2% (N=47) of MMS were performed with a margin of 1 cm or less, 19.2% (N=20) were performed with a margin of 1 cm or more, and the remaining had unspecified margins. The most common primary site for MMS was skin of the trunk (33.7%, N=35), followed by the upper limb and shoulder (16.3%, N=17), and the lower limb and hip (15.4%, N=16). All patients were alive at the last contact, with a median overall survival of 182 months (15.2 years). Discussion: MMS is used commonly in adults to treat a variety of skin tumors that can have aggressive traits such as melanoma. Although it offers low recurrence rates and tissue-sparing treatment in adult populations, MMS frequency has not changed within the pediatric population. MMS is mainly seen in privately insured, White patients with an early stage of melanoma; this is likely due to lower rates and delayed diagnosis in patients with darker skin that would otherwise present with metastatic disease. Given its clinical advantages and low rate of use, further research should address barriers that affect the availability of MMS in the pediatric population. Citation Format: Zachary G. Brandt, Xinxin Wu, Jared Kennard, Julia Griffin, Peter Silberstein. Mohs surgery trends in 104 cases of pediatric melanoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 3566.

Pediatric melanoma incidence and survival: a fifteen-year nationwide retrospective cohort study in Korea (2004-2019)

Pediatric melanoma incidence and survival: a fifteen-year nationwide retrospective cohort study in Korea (2004–2019)

Incidence and survival rates of primary cutaneous malignancies in Korea, 1999–2019: A nationwide population‐based study

Nationwide Trends in the Incidence of Melanoma and Non-melanoma Skin Cancers from 1999 to 2014 in South Korea

Pediatric Melanoma in Melanoma-Prone Families.

Epidemiology and Prognostic Factors of Malignant Melanoma Among 200 Asian Patients from a Single Medical Center

Cutaneous melanoma in adolescents and young adults

Clinical characteristics, prognosis, and immunotherapy outcome in pediatric melanoma: Analysis from a large Chinese cohort.

High Risk of Non-Melanoma Skin Cancer in Actinic Keratosis Patients with Skin of Color: A Nationwide Register-Based Cohort Study

Genetic Characteristics of Primary Cutaneous Malignant Melanoma in Koreans Compared With Western Populations

Epidemiology and Survival Outcomes for Eyelid Primary Malignant Melanoma: an Analysis of 1397 Cases in the SEER Database

Epidemiologic and Clinical Outcomes of Pediatric Renal Tumors in Korea: A Retrospective Analysis of The Korean Pediatric Hematology and Oncology Group (KPHOG) Data

Epidemiological characteristics and hospitalization burden analysis of pediatric inpatients with melanocytic nevi in China from 2016 to 2021: A nationwide retrospective study of 13,396 cases

Clinicopathological Analysis of 719 Pediatric and Adolescents’ Ocular Tumors and Tumor-Like Lesions: a Retrospective Study from 2000 to 2018 in China

Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2014

The reduced mortality of malignant melanoma at the population level is mainly attributable to treatment advances for the past decade

Analysis and prediction of 5-year survival in patients with cutaneous melanoma: a model-based period analysis

Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015

Abstract 3566: Mohs surgery trends in 104 cases of pediatric melanoma

Pediatric Keloids: A Retrospective, Single‐Institution Cohort Analysis in Korea

EPID-21. EPIDEMIOLOGY OF MALIGNANT GLIOMAS IN KOREA USING NATIONWIDE BIG DATA FROM 2007 TO 2017